Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'

Why did Nvidia's stock rally fade quickly? How could Trump's Ukraine peace plan affect markets? What caused Bitcoin's recent flash crash below $82,000? Why is Verizon cutting 13,000 jobs now? How is AI spending impacting global stock volatility? What drove Walmart to switch to Nasdaq listing? Why did IBM and Cisco team on quantum computing?

Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'

benzinga.com/news/health-care/25/11/48986480/short-seller-alleges-praxis-precisions-potential-3-billion-drug-a-house-of-cards

A short seller is challenging Praxis Precision Medicines Inc. (NASDAQ:PRAX) after the company claimed success from its Phase 3 trial of ulixacaltamide.
PRAX shares are retreating from recent levels. Watch the momentum here
Culper Research report argues that the data underpinning its…

This story appeared on benzinga.com, 2025-11-20 18:55:05.